Zhang Ning, Ahsan Muhammad H, Zhu Leanne, Sambucetti Lidia C, Purchio Anthony F, West David B
Xenogen Corporation, Alameda, California 94501, USA.
J Biol Chem. 2005 Jun 3;280(22):21400-8. doi: 10.1074/jbc.M411952200. Epub 2005 Mar 29.
The GADD45 (growth arrest and DNA damage-inducible) family of genes is involved in the regulation of cell cycle progression and apoptosis. To study signaling pathways affecting GADD45beta expression and to examine systematically in vivo the GADD45beta expression in tissues following various toxic stresses, we created a transgenic mouse by fusing the GADD45beta promoter to firefly luciferase (Gadd45beta-luc). In vivo GADD45beta expression was assessed by measuring the luciferase activity in the Gadd45beta-luc transgenic mouse using a non-invasive imaging system (IVIS Imaging System, Xenogen Corporation). We found that a number of agents that induce oxidative stress, such as sodium arsenite, CCl4, lipopolysaccharide (LPS), or tumor necrosis factor-alpha, are able to induce luciferase expression throughout the entire animal. In liver, spleen, lung, intestine, kidney, and heart, we observed an induction of luciferase activity after LPS treatment, which correlates with an increase of GADD45beta mRNA in these tissues. Processes that induce DNA damage activate the NF-kappaB signaling pathway. Several inhibitors of the NF-kappaB signaling pathway, including dexamethasone, thalidomide, and a proteasome inhibitor, bortezomib, showed inhibitory effects on LPS-induced GADD45beta expression as indicated by a decrease of the luciferase activity. Northern blot analysis confirmed a broad inhibitory effect of bortezomib on LPS-induced GADD45beta mRNA expression in spleen, lung, and intestine. In liver of bortezomib-treated mice, we observed a reverse correlation between the luciferase activity and the GADD45beta mRNA level. We speculate that such a discrepancy could be due to severe liver toxicity caused by bortezomib and LPS co-treatment. MAPK inhibitors had transient and inconsistent effects on LPS-induced luciferase expression. Our data are consistent with the notion that NF-kappaB, but not the MAPK signaling pathways, is involved in the in vivo regulation of GADD45beta expression. Thus, NF-kappaB signaling involves induction of GADD45beta expression, which supports the proposed role of GADD45beta in protecting cells against DNA damaged under various stress conditions.
GADD45(生长停滞和DNA损伤诱导)基因家族参与细胞周期进程和细胞凋亡的调控。为了研究影响GADD45β表达的信号通路,并系统地检测各种毒性应激后体内组织中GADD45β的表达情况,我们通过将GADD45β启动子与萤火虫荧光素酶融合,创建了一种转基因小鼠(Gadd45β-luc)。使用非侵入性成像系统(IVIS成像系统,Xenogen公司)通过测量Gadd45β-luc转基因小鼠体内的荧光素酶活性来评估体内GADD45β的表达。我们发现,许多诱导氧化应激的试剂,如亚砷酸钠、四氯化碳、脂多糖(LPS)或肿瘤坏死因子-α,都能够在整个动物体内诱导荧光素酶表达。在肝脏、脾脏、肺、肠道、肾脏和心脏中,我们观察到LPS处理后荧光素酶活性的诱导,这与这些组织中GADD45β mRNA的增加相关。诱导DNA损伤的过程会激活NF-κB信号通路。几种NF-κB信号通路抑制剂,包括地塞米松、沙利度胺和蛋白酶体抑制剂硼替佐米,均对LPS诱导的GADD45β表达具有抑制作用,表现为荧光素酶活性降低。Northern印迹分析证实硼替佐米对脾脏、肺和肠道中LPS诱导的GADD45β mRNA表达具有广泛的抑制作用。在硼替佐米处理的小鼠肝脏中,我们观察到荧光素酶活性与GADD45β mRNA水平呈负相关。我们推测这种差异可能是由于硼替佐米和LPS联合处理导致的严重肝脏毒性。MAPK抑制剂对LPS诱导的荧光素酶表达具有短暂且不一致的影响。我们的数据与以下观点一致,即NF-κB而非MAPK信号通路参与体内GADD45β表达的调控。因此,NF-κB信号通路涉及GADD45β表达的诱导,这支持了GADD45β在各种应激条件下保护细胞免受DNA损伤的作用。